BioWorld Asia

July 19, 2006

Actelion, Roche Sign $630M Autoimmunity Product Deal

Shrugging off recent disappointments in the clinic, Actelion AG signed what is likely to be one of the landmark licensing deals in European biotechnology in 2006. (BioWorld International) Read More

DeCode Stock Sale To Raise $30M For Multidrug Pipeline

Motility Control Proteins Might Play Part In Pancreatic Cancer

Crucell Shares Fall After Aerugen Program Ended

ProStrakan Secures Deal, Raises £11M In Placement

Nasdaq In Lead, But Potential LSE Merger Raises Questions

Cellectis, Lexicon Genetics Exchange Rights To Patents

Devices In Past, Medisys Now Complete As Investing Firm

Advanced Therapies Under Scrutiny At EU Parliament

Astion Brings In DKK50M For Dermatology Pipeline

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 7, 2025.

House passes H.R. 1, restoring R&D tax cuts

BioWorld MedTech

The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...

3D rendering of a molecular glue mediating the interaction between two proteins

With surface mimicry, molecular glues shed hairpin need

BioWorld Science

Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...

Illustration of the β2-adrenergic receptor

Exercise-mimicking compound offers alternative to GLP-1 therapies

BioWorld

An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...